Expression analysis of potential novel biomarkers TRIM29 alongside lncRNA NORAD and MIR497-HG in breast, gastric, and colorectal cancers
This study evaluated TRIM29, NORAD, and MIR497HG as diagnostic biomarkers in breast, gastric, and colorectal cancers using bioinformatics and RT-qPCR. MIR497HG was consistently downregulated, while NORAD and TRIM29 showed cancer-specific expression patterns.
Nafiseh Sharifi, Pooria Parvaz, Danial Khezrian, Behnaz Saeidi Palomi, Niloofar Nasr Esfahani, Helia Ebrahimi, Ghazal Delgoshae, Erfan Dehghan, Sayedeh Zahra Shirdeli, Mohammad Rezaei, Mansoureh Azadeh, Reza Rasoolzadeh · October 25, 2026
Background The rising cancer incidence and mortality rates support continued investigation of molecular markers in breast cancer (BC), gastric cancer (GC), and colorectal cancer (CRC). mRNAs and lncRNAs are involved in cancer-related regulation, and altered expression of TRIM29, NORAD, and MIR497HG has been reported in different tumor types. This study evaluated these three transcripts as candidate diagnostic biomarkers in BC, GC, and CRC using public expression datasets and RT-qPCR validation. Methods Bioinformatics and RT-qPCR analyses showed cancer type-specific expression patterns. MIR497HG was downregulated in BC, GC, and CRC in both public-data analysis and RT-qPCR validation. NORAD was significantly upregulated in GC and CRC, while its change in BC was not significant by RT-qPCR. TRIM29 was downregulated in BC and upregulated in CRC by RT-qPCR. In GC, GEO …